L A Ferrara1, B Capaldo2, C Mancusi3, E T Lee4, B V Howard5, R B Devereux6, G de Simone7. 1. Department of Clinical Medicine and Surgery, Federico II University Hospital, Via S. Pansini 5, 80131 Naples, Italy. Electronic address: ferrara@unina.it. 2. Department of Clinical Medicine and Surgery, Federico II University Hospital, Via S. Pansini 5, 80131 Naples, Italy. 3. Department of Translational Medical Sciences, Federico II University, Naples, Italy. 4. Center for American Indian Health Research, University of Oklahoma, Oklahoma City, OK, USA. 5. Medstar Research Institute, Washington, D.C., USA. 6. Department of Medicine, Weill Cornell Medical College, New York, NY, USA. 7. Department of Translational Medical Sciences, Federico II University, Naples, Italy; Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
Abstract
BACKGROUND AND AIM: Sarcopenia is a condition mainly due to loss of fat-free mass (FFM) in elderly individuals. RFFMD, however, is also frequent in obese subjects due to abnormal body composition. Objective of this study was to evaluate the impact of relative fat-free mass deficiency (RFFMD) on cardiometabolic (CM) risk in obese normoglycemic individuals. METHODS AND RESULTS: Overweight/obese American Indians from the Strong Heart Study population, without diabetes and with FBG ≤ 110 mg/dL and with GFR >60 mg/mL/1.73 m(2) were selected for this analysis (n = 742). RFFMD was defined on the basis of a multivariable equation previously reported. Fasting glucose and 2 h-OGTT were measured together with urine albumin/creatinine excretion, laboratory and anthropometric parameters. In addition to lower FFM and greater adipose mass, participants with RFFMD had higher body mass index, waist circumference, C-reactive protein, fibrinogen, insulin resistance and urinary albumin/creatinine than participants with normal FFM (all p < 0.001); they also had a greater prevalence of hypertension, impaired glucose tolerance (IGT) or OGTT-diabetes than participants with normal FFM (all p < 0.003) and a near 2-fold greater probability of significant proteinuria (p < 0.01). RFFMD was more frequent in women than in men: significant sex-RFFMD interactions were found for BMI and waist circumference (both p < 0.0001). CONCLUSIONS: RFFMD in overweight/obese normoglycemic individuals is associated with greater probability of hypertension, abnormalities of glucose tolerance and proteinuria. Assessment of RFFRMD might, therefore, help stratifying cardiometabolic risk among normoglycemic individuals with overweight/obesity.
BACKGROUND AND AIM: Sarcopenia is a condition mainly due to loss of fat-free mass (FFM) in elderly individuals. RFFMD, however, is also frequent in obese subjects due to abnormal body composition. Objective of this study was to evaluate the impact of relative fat-free mass deficiency (RFFMD) on cardiometabolic (CM) risk in obese normoglycemic individuals. METHODS AND RESULTS: Overweight/obese American Indians from the Strong Heart Study population, without diabetes and with FBG ≤ 110 mg/dL and with GFR >60 mg/mL/1.73 m(2) were selected for this analysis (n = 742). RFFMD was defined on the basis of a multivariable equation previously reported. Fasting glucose and 2 h-OGTT were measured together with urine albumin/creatinine excretion, laboratory and anthropometric parameters. In addition to lower FFM and greater adipose mass, participants with RFFMD had higher body mass index, waist circumference, C-reactive protein, fibrinogen, insulin resistance and urinary albumin/creatinine than participants with normal FFM (all p < 0.001); they also had a greater prevalence of hypertension, impaired glucose tolerance (IGT) or OGTT-diabetes than participants with normal FFM (all p < 0.003) and a near 2-fold greater probability of significant proteinuria (p < 0.01). RFFMD was more frequent in women than in men: significant sex-RFFMD interactions were found for BMI and waist circumference (both p < 0.0001). CONCLUSIONS: RFFMD in overweight/obese normoglycemic individuals is associated with greater probability of hypertension, abnormalities of glucose tolerance and proteinuria. Assessment of RFFRMD might, therefore, help stratifying cardiometabolic risk among normoglycemic individuals with overweight/obesity.
Authors: Giovanni de Simone; Fabrizio Pasanisi; Aldo L Ferrara; Mary J Roman; Elisa T Lee; Franco Contaldo; Barbara V Howard; Richard B Devereux Journal: Int J Cardiol Date: 2012-10-09 Impact factor: 4.164
Authors: Brunella Capaldo; Procolo Di Bonito; Michele Iaccarino; Mary J Roman; Elisa T Lee; Richard B Devereux; Gabriele Riccardi; Barbara V Howard; Giovanni de Simone Journal: Diabetes Care Date: 2012-12-05 Impact factor: 19.112
Authors: Giovanni de Simone; Wenyu Wang; Lyle G Best; Fawn Yeh; Raffaele Izzo; Costantino Mancusi; Mary J Roman; Elisa T Lee; Barbara V Howard; Richard B Devereux Journal: Cardiovasc Diabetol Date: 2017-05-12 Impact factor: 9.951
Authors: Karen K Miller; Miriam A Bredella; Melanie S Haines; Laura E Dichtel; Kate Santoso; Martin Torriani Journal: Int J Obes (Lond) Date: 2020-05-13 Impact factor: 5.095
Authors: Costantino Mancusi; Giovanni de Simone; Lyle G Best; Wenyu Wang; Ying Zhang; Mary J Roman; Elisa T Lee; Barbara V Howard; Richard B Devereux Journal: Cardiovasc Diabetol Date: 2019-04-30 Impact factor: 9.951
Authors: D Edmund Anstey; Rikki M Tanner; John N Booth; Adam P Bress; Keith M Diaz; Mario Sims; Gbenga Ogedegbe; Paul Muntner; Marwah Abdalla Journal: J Am Heart Assoc Date: 2019-08-13 Impact factor: 5.501
Authors: Costantino Mancusi; Maria Virginia Manzi; Giovanni de Simone; Carmine Morisco; Maria Lembo; Emanuele Pilato; Raffaele Izzo; Valentina Trimarco; Nicola De Luca; Bruno Trimarco Journal: J Am Heart Assoc Date: 2022-01-19 Impact factor: 6.106